Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Pieris Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PIRS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 32% a week.
Volatility Over Time: PIRS's weekly volatility has increased from 18% to 32% over the past year.
7 Day Return
1 Year Return
Return vs Industry: PIRS underperformed the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: PIRS underperformed the US Market which returned 39.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Pieris Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWe Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
2 months ago | Simply Wall StNeed To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
2 months ago | Simply Wall StWill Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
Is Pieris Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PIRS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PIRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PIRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PIRS is overvalued based on its PB Ratio (5.3x) compared to the US Biotechs industry average (2.9x).
How is Pieris Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PIRS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PIRS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PIRS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PIRS's revenue (28.1% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: PIRS's revenue (28.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PIRS's Return on Equity is forecast to be high in 3 years time
How has Pieris Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PIRS is currently unprofitable.
Growing Profit Margin: PIRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PIRS is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare PIRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PIRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: PIRS has a negative Return on Equity (-98.87%), as it is currently unprofitable.
How is Pieris Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: PIRS's short term assets ($88.3M) exceed its short term liabilities ($30.3M).
Long Term Liabilities: PIRS's short term assets ($88.3M) exceed its long term liabilities ($47.3M).
Debt to Equity History and Analysis
Debt Level: PIRS is debt free.
Reducing Debt: PIRS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PIRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PIRS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 31.2% each year
What is Pieris Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PIRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PIRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PIRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PIRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PIRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Yoder (45 yo)
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD1.11M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Management: PIRS's management team is considered experienced (2.7 years average tenure).
Experienced Board: PIRS's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.
Pieris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pieris Pharmaceuticals, Inc.
- Ticker: PIRS
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$213.332m
- Shares outstanding: 63.30m
- Website: https://www.pieris.com
Number of Employees
- Pieris Pharmaceuticals, Inc.
- 255 State Street
- 9th Floor
- United States
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low mol...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/24 22:46|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.